Skip to main content
. 2021 Jan 21;12(5):667–675. doi: 10.1111/1759-7714.13792

Table 1.

Baseline characteristics of all patients and clinical manifestation according to the GPS

Total GPS 0 GPS 1 GPS 2 P‐value
No. of patients 56 31 16 9 0.732
Age (years) 71 71 72 71
Median range 66–76 68–77 65–74
Sex (%)
Male 40 (71.4) 24 (77.4) 12 (75.0) 4 (44.4) 0.145
Female 16 (28.6) 7 (22.6) 4 (25.0) 5 (55.6)
Performance status (%) 0.303
0, 1 49 (87.5) 29 (93.5) 13 (81.3) 7 (77.8)
2–4 7 (12.5) 2 (6.5) 3 (18.8) 2 (22.2)
Smoking status (%) 0.790
Never smoked 3 (5.4) 2 (6.5) 0 (0.0) 1 (11.1)
Former smoker 41 (73.2) 23 (74.2) 12 (75.0) 6 (66.7)
Current smoker 12 (21.4) 6 (19.4) 4 (25.0) 2 (22.2)
Pack‐years 50.0 50.0 49.5 53.0 0.702
Median range 36.7–82.5 38.1–58.7 15.0–60.2
BMI (kg/m2) 23.1 23.9 22.8 20.8 0.089
Median range 19.6–25.7 21.5–23.8 19.8–22.4
Histology (%) 0.305
Adenocarcinoma 28 (50.0) 17 (54.8) 5 (31.3) 6 (66.7)
Squamous cell carcinoma 25 (44.6) 13 (41.9) 9 (56.3) 3 (33.3)
Clinical stage (%) 0.788
III 10 (17.9) 6 (19.4) 2 (12.5) 2 (22.2)
IV or recurrence 46 (82.1) 25 (80.6) 14 (87.5) 7 (77.8)
WBC (/μL) 7100 6400 8400 7700 0.034
Median range 5500–7500 5825–9750 7350–9100
Neutrophils (/μL) 4436 4015 6085 5035 0.018
Median range 3478–4831 4065–7407 3033–6781
Lymphocytes (/μL) 1505 1650 1413 1243 0.122
Median range 1232–2056 970–1731 535–1974
Eosinophils (/μL) 137 159 129 100 0.845
Median range 83–258 51–251 37–242
KL‐6 (U/mL) 624 591 600 1034 0.301
Median range 462–843 433–961 564–1480
%predicted FVC (%) 103.1 104.6 98.5 84.3 0.612
Median range 95.0–111.0 79.8–126.5 55.8–121.3
HRCT pattern (%) 0.331
UIP pattern 25 (44.6) 12 (38.7) 7 (43.7) 6 (66.7)
Non‐UIP pattern 31 (55.4) 19 (61.3) 9 (56.2) 3 (33.3)
Emphysema (%) 0.752
Yes 45 (80.4) 26 (83.9) 12 (75.0) 7 (77.8)
No 11 (19.6) 5 (16.1) 4 (25.0) 2 (22.2)

BMI, body mass index; FVC, forced vital capacity; GPS, Glasgow Prognostic Score; HRCT, high‐resolution computed tomography; KL‐6, Krebs von den Lungen‐6; UIP, usual interstitial pneumonia; WBC, white blood cell.